Fig. 5

Nexturastat A enhances the antitumor efficacy of anti-CD47 in SM1 melanoma-bearing mice. A Schematic representation of treatment timeline. B Tumor growth kinetics of SM1 melanoma tumors (n = 9–12 mice per group) treated with vehicle control, Nexturastat A (NextA, 20 mg/kg, IP), anti-CD47 (100 µg intratumoral), or combination. C Individual tumor growth kinetics in the different groups. Immunophenotyping of tumors was performed by flow cytometry at day 24 post-tumor implantation. The immune cell populations include total CD45+ immune cells (D) M1-like, M2-like, and M1/M2 ratio (E) total CD3+ T cells (F) total CD4+ T cells (G) total CD8+ T cells (H) T-regs (I) effector memory (EM) and central memory (CM) CD4+ T cells (J) effector memory (EM) and central memory (CM) CD8+ T cells (K) total NK cells NK cells (L) and total NKT, CD8+ NKT, and CD137+ CD8 + NKT (M). The surface markers used to identify the populations are indicated on the y axis of every graph. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, non-significant